Omics Analysis Services for Bladder Cancer

Omics Analysis Services for Bladder Cancer

Omics analysis refers to the comprehensive study of large-scale biological data generated from various high-throughput technologies, such as genomics, transcriptomics, proteomics, and metabolomics. Alfa Cytology provides comprehensive preclinical CRO services in the field of bladder cancer, offering a wide range of omics analysis services.

Omics Analysis in Bladder Cancer

Bladder cancer is the most common urinary tract malignancy, with a substantial global burden. Traditional diagnostic and therapeutic methods have limitations in terms of accuracy and sensitivity. Therefore, there is a need for innovative approaches that can provide more comprehensive and precise information about bladder cancer.

Omics analysis, encompassing genomics, transcriptomics, proteomics, metabolomics, and microbiomics, offers a holistic view of the molecular landscape of bladder cancer. By analyzing these different omics layers, researchers can uncover molecular signatures, identify potential biomarkers, understand disease mechanisms, and develop targeted therapies.

Services

DNA

Genomics

Services

RNA

Transcriptomics

Services

Protein

Proteomics

Services

Metabolite

Metabolomics

Services

Cell

Single-Cell Omics

Services

Tissue

Spatial omics

Fig.1 Our omics analysis includes genomics, transcriptomics, proteomics, metabolomics, single-cell omics, and spatial omics.

Analysis Description Applications
Genomic Analysis Study of genetic material (DNA) of bladder cancer cells. Diagnosis, prognosis, identification of genetic markers.
Transcriptomic Analysis Study of gene expression patterns in bladder cancer cells. Understanding molecular mechanisms, pathways in bladder cancer development and progression.
Proteomic Analysis Study of the entire set of proteins expressed in bladder cancer cells. Biomarker discovery, early detection, prognostication, therapeutic response monitoring.
Metabolomic Analysis Study of small molecules (metabolites) in bladder cancer cells. Insights into metabolic reprogramming, potential therapeutic targets.

Our Services

Alfa Cytology has been developing new diagnostic tools and treatments for bladder cancer through a multidisciplinary, collaborative approach that combines a number of technologies, including genomics, transcriptomics, proteomics, single-cell histology, bioinformatics and biostatistics.

Genomic

  • Whole Exome Sequencing
  • Targeted Gene Sequencing
  • Whole Genome Sequencing
  • Bladder Cancer Genotyping

Transcriptomics

  • Whole Transcriptome Analysis
  • Target Gene Expression Analysis
  • Non-Coding RNA Analysis
  • Transcriptome Profiling Array

Proteomic

  • Discovery Proteomics
  • Targeted Proteomics
  • Post Translational Modifications (PTM) Analysis
  • Exosomes Proteomics Analysis

Metabonomic

  • Untargeted Metabolomics Profiling
  • Targeted Metabolomics
  • Lipidomics Analysis Services

Multi-omics Analysis

  • Transcriptome and Metabolome Integration Analysis
  • Proteome and Metabolome Integration Analysis

Single-Cell Omics

  • Single-Cell Transcriptome Sequencing
  • Single-Cell Immunome Sequencing
  • Single-Cell Epigenome Sequencing
  • Single-Cell Genome Sequencing

Spatial Omics

  • Spatial Transcriptomics
  • In Situ Sequencing
  • Spatial Proteomics
  • Advanced FISH Technologies
  • Spatial Mass Spectrometry

Bioinformatics

  • Bioinformatics Services
  • Biostatistics Services

Our Service Workflow

Tell us what you need

Tell Us What You Need

Provide solutions

Provide Solutions

Sign the contract and send sample

Sign the Contract and Send Sample

One-stop service

One-Stop Service

Project Final Report

Project Final Report

Contact Us

If you are interested in leveraging the power of omics analysis for bladder cancer research, Alfa Cytology is here to assist you. Contact us today to discuss your specific needs and learn more about how our comprehensive preclinical CRO services can accelerate your research projects, facilitate early diagnosis, and contribute to the development of effective therapies for bladder cancer.

Reference

  1. Yu E. Y., Zhang H., and et al. Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study. Curr Oncol. 2022, 29(8): 5442-5456.
For research use only. Not intended for any clinical use.
Related Services
About Us

Alfa Cytology is dedicated to drug development and preclinical services for bladder cancer.

Contact Us
  • twitter
Copyright © Alfa Cytology. All Rights Reserved.
Top